Both J12-derived formulations alleviated DNFB-induced AD symptoms: Topical J12S significantly reduced ear swelling, serum IL-4 and IL-17 levels, and increased the proportion of splenic Treg cells. Here, IL17A is linked to Alzheimer disease.